BIOHYBRID GETS ANOTHER MILESTONE PAYMENT FROM MICROMET GMBH.Biohybrid, Inc., Denver, Colorado, has received another milestone payment from Micromet GmbH, Munich, Germany, for the exclusive general license to Biohybrid's Activating Hybrid Antibody. The agreement will bring in up-front and royalty payments of $3 million. Biohybrid's product platform of hybrid antibodies and genetically engineered genetically engineered adjective Recombinant, see there vectors are agents for the treatment of graft rejection graft rejection Rejection Clinical immunology The constellation of defenses mounted by the immune system of the recipient of an allograft–eg kidney, liver, pancreas, etc, which compromise the continued viability of grafted tissue. Cf Graft. , graft-versus-host disease graft-versus-host disease n. A type of incompatibility reaction of transplanted cells against host tissues that possess an antigen not possessed by the donor. Also called graft-versus-host reaction. , and autoimmune disorders. Its products selectively suppress a subset of white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies that are programmed to destroy the graft. Dr. Paula Konigsberg, director of Drug Development for the company, stated that, "We are very pleased to have developed this relationship with Micromet. Our technologies are compatible and we will be able to help each other in our developmental programs." For more information, call 303/336-5735. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion